Yvonne Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yvonne Li has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Andrew D. Cherniack
Broad Institute of MIT and Harvard, Cambridge, MA, USA
433 shared publications - Hersh Gupta
Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts
404 shared publications - Geoffrey I. Shapiro
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
398 shared publications - Scott Rodig
Harvard Medical School, Boston, Massachusetts
272 shared publications - Lynette M. Sholl
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
259 shared publications - Adam Jacob Schoenfeld
Memorial Sloan Kettering Cancer Center, New York, New York, USA
253 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Purpose:PARP inhibition has demonstrated efficacy in patients with platinum-sensitive pancreatic cancer with germline BRCA1/2 pathogenic variants (PV). Whether PARP inhibitors might be effective in a broader population of patients with pancreatic cancer remains under investigation.Patients and Methods:This multicenter, open-label phase II trial (NCT03601923) enrolled patients with advanced pancreatic cancers who harbored germline or somatic BRCA1, BRCA2, PALB2, ATM, and/or CHEK2 PVs. Patients with prior progression on platinum-based therapy were excluded. Patients were treated with niraparib 200 or 300 mg once daily, with their initial dose determined by weight and platelet count. The primary endpoint was 6-month progression-free survival (PFS).Results:Thirty-two patients [10 women (31%); median age: 67 years] were enrolled. Patients had a PV in at least one of the following genes: ATM (n = 14), BRCA2 (n = 10), PALB2 (n = 3), CHEK2 (n = 4), or BRCA1 (n = 2). The 6-month PFS was 25% [90% confidence interval (CI), 13%–41%] for the overall population, exceeding the preestablished threshold of 17%. The median PFS for the entire population was 2 months (95% CI, 1.4–3.8), and the objective response rate was 14% (95% CI, 4%–33%). All six patients with ≥6 months of PFS and evaluable tumor zygosity had biallelic inactivation of a DNA repair gene. Three patients with biallelic inactivation of ATM and no progression on prior chemotherapy received niraparib for more than 1 year.Conclusions:Niraparib demonstrated clinically meaningful benefit in a subset of patients. The prolonged PFS observed in patients with biallelic ATM loss warrants further investigation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Purpose:PARP inhibition has demonstrated efficacy in patients with platinum-sensitive pancreatic cancer with germline BRCA1/2 pathogenic variants (PV). Whether PARP inhibitors might be effective in a broader population of patients with pancreatic cancer remains under investigation.Patients and Methods:This multicenter, open-label phase II trial (NCT03601923) enrolled patients with advanced pancreatic cancers who harbored germline or somatic BRCA1, BRCA2, PALB2, ATM, and/or CHEK2 PVs. Patients with prior progression on platinum-based therapy were excluded. Patients were treated with niraparib 200 or 300 mg once daily, with their initial dose determined by weight and platelet count. The primary endpoint was 6-month progression-free survival (PFS).Results:Thirty-two patients [10 women (31%); median age: 67 years] were enrolled. Patients had a PV in at least one of the following genes: ATM (n = 14), BRCA2 (n = 10), PALB2 (n = 3), CHEK2 (n = 4), or BRCA1 (n = 2). The 6-month PFS was 25% [90% confidence interval (CI), 13%–41%] for the overall population, exceeding the preestablished threshold of 17%. The median PFS for the entire population was 2 months (95% CI, 1.4–3.8), and the objective response rate was 14% (95% CI, 4%–33%). All six patients with ≥6 months of PFS and evaluable tumor zygosity had biallelic inactivation of a DNA repair gene. Three patients with biallelic inactivation of ATM and no progression on prior chemotherapy received niraparib for more than 1 year.Conclusions:Niraparib demonstrated clinically meaningful benefit in a subset of patients. The prolonged PFS observed in patients with biallelic ATM loss warrants further investigation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S1: CONSORT diagram indicating patient disposition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S1: CONSORT diagram indicating patient disposition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S6: Genomic characterization of BRCA2 reversion mutations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S6: Genomic characterization of BRCA2 reversion mutations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S2: Kaplan-Meier estimates of overall survival (OS) in patients treated with niraparib across the entire trial population
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S2: Kaplan-Meier estimates of overall survival (OS) in patients treated with niraparib across the entire trial population
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S3: Outcomes based on chemotherapy sensitivity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Supplementary Figure S3: Outcomes based on chemotherapy sensitivity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.